FDA Approves CAR T-Cell Therapy for Non-Hodgkin Lymphoma – www.oncnursingnews.com/
|
FDA Approves CAR T-Cell Therapy for Non-Hodgkin Lymphoma
www.oncnursingnews.com/ The FDA has approved the CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) for people with large B-cell lymphoma following 2 prior therapies, including for those with diffuse large B-cell lymphoma (DLBCL). It is also … FDA Approves Yescarta™, Revolutionary CAR–T Immunotherapy for Non-Hodgkin's Lymphoma Patients FDA Approves Axi-Cel for Large B-cell Lymphoma |
